Engineering thymopoietics to induce thymus rejuvenation.

TECregen is advancing thymopoietic therapies by developing best-in-class and novel agents derived from their proprietary single-cell data library of thymic epithelial cells. Leveraging expertise in thymic cytokine biology and protein engineering, they are optimizing natural thymopoietics to enhance half-life, efficacy, and safety while reducing off-target effects, as well as engineering novel synthekines.